Niagen Bioscience, Inc. (NASDAQ: NAGE), a noteworthy player in the biotechnology sector, is gaining traction among investors for its innovative approach in the healthcare industry. With a market capitalization of $906.64 million, this Los Angeles-based company is a frontrunner in developing products aimed at promoting healthy aging.
Currently trading at $11.51, Niagen Bioscience has experienced a price change of -0.21 (-0.02%) recently. Despite this slight dip, the stock has shown resilience with a 52-week range spanning from $2.44 to $11.78, indicating significant volatility and growth potential.
While the company does not currently offer a trailing P/E ratio or PEG ratio, its forward P/E ratio stands at 56.61, suggesting that investors are optimistic about future earnings growth. This optimism is further supported by its remarkable revenue growth of 37.60%, a strong signal of the company’s expanding market presence and operational success.
One of the standout metrics for Niagen Bioscience is its return on equity (ROE) at 33.47%, which demonstrates efficient management and profitability relative to shareholder equity. The company also boasts a free cash flow of $15.43 million, providing a solid foundation for future investments and operational flexibility.
Niagen Bioscience’s dividend policy is currently non-existent, with a payout ratio of 0.00%, indicating that the company is reinvesting its earnings to fuel growth rather than distributing them to shareholders. This strategy aligns with its aggressive expansion and product development plans.
Analyst sentiment surrounding NAGE stock is overwhelmingly positive, with four buy ratings and no hold or sell ratings. The target price range is set between $9.60 and $23.00, with an average target of $14.15, suggesting a potential upside of 22.94%. This forecast underlines the confidence in the company’s growth trajectory and market potential.
In terms of technical indicators, Niagen Bioscience’s 50-day moving average is $8.41, and its 200-day moving average is $6.12, both of which are below the current trading price, indicating a bullish trend. The Relative Strength Index (RSI) at 43.93 suggests that the stock is neither overbought nor oversold, providing a balanced entry point for investors.
Niagen Bioscience operates through three distinct segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. It offers finished dietary supplement products, NAD+ test kits, and commercializes proprietary ingredient technologies. The company’s flagship product, TRU NIAGEN, is distributed through various channels, including its e-commerce platform, Amazon, and specialty retailers, enhancing its market reach.
Formerly known as ChromaDex Corporation, Niagen Bioscience rebranded in March 2025, reflecting its commitment to innovation and leadership in the bioscience field. Founded in 1999, the company continues to leverage its expertise to deliver cutting-edge solutions for healthy aging, making it a compelling option for investors seeking exposure to the biotechnology sector.
For those looking to invest in a company with a strong growth outlook and innovative product offerings, Niagen Bioscience, Inc. presents a promising opportunity. With a solid foundation in the healthcare industry and a strategic focus on expansion, NAGE is poised to capitalize on the increasing demand for health-focused bioscience solutions.
